SURMOUNT-1 (tirzepatide, 72 weeks): Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Key characteristics: GI events occur primarily during dose escalation The GIP component does not appear to add substantial GI burden beyond GLP-1 effects Pooled SURMOUNT-1 to -4 analysis showed treatment discontinuation due to GI AEs ranged from 1.0% to 10.5% Retatrutide# Retatrutide adds glucagon receptor agonism to GLP-1 and GIP, creating a triple agonist
If you are considering LIPO-B (MIC + B12), the first step is a free assessment
A receiver operating characteristic curve was generated for plasma activity of SOD, GPx, and combined tests
Key takeaways MeAgain is the GLP-1 tracker app built specifically for the daily routine: shots or pills, dose history, injection sites, food, protein, fiber, water, side effects, weight, and progress not generic dieting
Applicable Procedure Codes: 61885, 61886, 64553, 64568, 64570, A4541, E0733, E0735, E0770, E1399, L8679, L8680, L8682, L8683, L8685, L8686, L8687, L8688
Subcutaneous P-21 (periodic, to stimulate hippocampal neurogenesis)
